Oncternal Therapeutics Inc. (ONCT) Reports Q4 Loss of $0.27

Oncternal Therapeutics Inc. (NASDAQ: ONCT) reported Q4 EPS of ($0.27), versus $0.21 reported last year.

“We are very pleased with recent clinical results from our pipeline of novel cancer treatments for patients with critical unmet medical need,” said James Breitmeyer, M.D., Ph.D., President and CEO, Oncternal. “We have seen encouraging results in all four of our clinical indications, including mantle cell lymphoma (“MCL”), Ewing sarcoma, breast cancer and chronic lymphocytic leukemia (“CLL”). We look forward to steadily advancing these programs in 2020 and expect to have multiple data updates throughout the year. Preclinical work is also identifying additional clinical targets for our existing product candidates and for our ROR1 CAR-T program.”

For earnings history and earnings-related data on Oncternal Therapeutics Inc. (ONCT) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded